Advancing Regenerative Medicine

Showing 1 - 39 of 39 trials

• Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders

  Stanford is currently not accepting patients for this trial.

• Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

  Stanford is currently accepting patients for this trial.

• JSP191 Antibody Targeting Conditioning in SCID Patients

  Stanford is currently accepting patients for this trial.

• Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

  Stanford is currently accepting patients for this trial.

• Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

  Stanford is currently accepting patients for this trial.

• Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

  Stanford is currently accepting patients for this trial.

• Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)

  Stanford is currently accepting patients for this trial.

• Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

  Stanford is currently accepting patients for this trial.

• Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

  Stanford is currently not accepting patients for this trial.

• Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  Stanford is currently not accepting patients for this trial.

• PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

  Stanford is currently not accepting patients for this trial.

• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

  Stanford is currently not accepting patients for this trial.

• Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  Stanford is currently not accepting patients for this trial.

• Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

  Stanford is currently accepting patients for this trial.

• Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

  Stanford is currently not accepting patients for this trial.

• MM CAR-T to Upgrade Response BMTCTN1902

  Stanford is currently not accepting patients for this trial.

• Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

  Stanford is currently accepting patients for this trial.

• Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

  Stanford is currently accepting patients for this trial.

• FT819 in Subjects With B-cell Malignancies

  Stanford is currently not accepting patients for this trial.

• Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

  Stanford is currently not accepting patients for this trial.

• Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

  Stanford is currently accepting patients for this trial.

• CTL019 Out of Specification MAP for ALL or DLBCL Patients

  Stanford is currently accepting patients for this trial.

• Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation

  Stanford is currently not accepting patients for this trial.

• Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

  Stanford is currently accepting patients for this trial.

• Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction

  Stanford is currently accepting patients for this trial.

• HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

  Stanford is currently accepting patients for this trial.

• Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

  Stanford is currently accepting patients for this trial.

• CD4^LVFOXP3 in Participants With IPEX

  Stanford is currently accepting patients for this trial.

• GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)

  Stanford is currently accepting patients for this trial.

• DALY II USA/ MB-CART2019.1 for DLBCL

  Stanford is currently accepting patients for this trial.

• Gene Therapy for Pyruvate Kinase Deficiency (PKD)

  Stanford is currently not accepting patients for this trial.

• B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme

  Stanford is currently accepting patients for this trial.

• A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)

  Stanford is currently not accepting patients for this trial.

• Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

  Stanford is currently accepting patients for this trial.

• A Phase 1 Study of ADI-001 in B Cell Malignancies

  Stanford is currently not accepting patients for this trial.

• A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

  Stanford is currently not accepting patients for this trial.

• A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

  Stanford is currently not accepting patients for this trial.

• A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

  Stanford is currently not accepting patients for this trial.

• A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma

  Stanford is currently not accepting patients for this trial.